Clinical study of detorubicin. EORTC Clinical Screening Group. -

Clinical study of detorubicin. EORTC Clinical Screening Group.

Abstract	A phase II trial of detorubicin (DTR) has been conducted on 164 patients with solid tumors. Regressions greater than or equal to 50% were obtained in 23% of the breast carcinoma patients, in 17% of the head and neck carcinoma patients and melanoma patients, and in 6% of the uteri cervix carcinoma patients. DTR seems to be as toxic as adriamycin for bone marrow and heart, but might induce a little less alopecia.
Authors
Journal	Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer (Recent Results Cancer Res) Vol. 74 Pg. 184-91 ( 1980) ISSN: 0080-0015 [Print] Germany
PMID	7444139 (Publication Type: Journal Article)
Chemical References	Antibiotics, Antineoplastic detorubicin Daunorubicin
Topics	Antibiotics, Antineoplastic (adverse effects, therapeutic use) Daunorubicin (adverse effects, analogs & derivatives, therapeutic use) Drug Evaluation Humans Neoplasms (drug therapy)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!